Global Leading Market Research Publisher QYResearch announces the release of its latest report “Colon-Soluble Gelatin Empty Capsules – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. For pharmaceutical formulation scientists, drug delivery specialists, and investors focused on oral biologics and inflammatory bowel disease (IBD) therapeutics, a persistent challenge remains: delivering active pharmaceutical ingredients (APIs) to the colon without premature release in the stomach or small intestine. Traditional gelatin capsules dissolve in the stomach (pH 1–3), while enteric-coated capsules release in the small intestine (pH 5.5–6.5). Neither achieves colonic delivery. The solution lies in colon-soluble gelatin empty capsules—specially designed capsule dosage forms that release and absorb drugs specifically in the colon (large intestine), enabling treatment of colon-related diseases (ulcerative colitis, Crohn’s disease, colorectal cancer) and systemic absorption of drugs with poor upper GI bioavailability. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Colon-Soluble Gelatin Empty Capsules market, including market size, share, demand, industry development status, and forecasts for the next few years.
Market Size, Growth Trajectory, and Valuation (2024–2031):
The global market for Colon-Soluble Gelatin Empty Capsules was estimated to be worth US$ 317 million in 2024 and is forecast to a readjusted size of US$ 424 million by 2031 with a CAGR of 4.3% during the forecast period 2025-2031. This $107 million incremental expansion reflects steady growth driven by rising IBD prevalence, the expanding pipeline of colon-targeted drugs, and increasing adoption of oral biologics that require protection from gastric degradation. For context, the 4.3% CAGR aligns with overall specialty pharmaceutical packaging growth but specific segments (plant-based gelatin, probiotic delivery) are growing at 6–7% rates. For pharmaceutical CEOs and drug developers, this signals a stable, specialized excipient market with increasing relevance as oral delivery expands beyond traditional small molecules.
Product Definition – Colon-Specific Dissolution Technology
Colon-soluble gelatin empty capsules are specially designed capsule dosage forms to ensure that the drug is released and absorbed in the colon (a part of the large intestine) without premature release in the stomach or small intestine. This type of capsule has the property of colon dissolution and is mainly used to treat colon-related diseases or to achieve the targeted effect of certain drugs.
Mechanism of Colon Targeting:
Several technologies achieve colonic release:
- pH-Sensitive Polymers: Capsules coated with polymers that dissolve at pH 6.8–7.2 (distal ileum to colon). However, inter-individual pH variability limits reliability.
- Time-Dependent (Delayed Release): Capsules with dissolution lag time of 5–6 hours after gastric emptying, correlating to colonic arrival.
- Enzyme-Triggered (Bacterial Degradation): Capsules formulated with polymers degraded by colonic microflora (e.g., azopolymers, pectin, chitosan). Most selective and widely adopted.
- Multi-Unit Systems: Pellets within capsules with varying release profiles.
Key Industry Characteristics and Strategic Drivers:
1. Material Type Segmentation – Animal-Based vs. Plant-Based Gelatin
The Colon-Soluble Gelatin Empty Capsules market is segmented as below:
By Material Type:
- Animal-Based Gelatin (largest segment, ~70% of market revenue): Derived from bovine or porcine collagen. Established manufacturing processes, lower cost, excellent mechanical properties. Growing at 3–4% CAGR. Preference varies by region (India and Middle East prefer bovine; Europe has porcine acceptance; Muslim-majority markets require halal-certified bovine).
- Plant-Based Gelatin (fastest-growing, ~30%, 7–8% CAGR): Hydroxypropyl methylcellulose (HPMC) or pullulan-based capsules. Advantages: vegetarian/vean labeling, no zoonotic disease risk (BSE/TSE), consistent dissolution profiles, and compatibility with hygroscopic fills. Price premium (20–30% over animal-based). A November 2025 announcement from Lonza (Capsugel) expanded plant-based colon-soluble capsule production capacity by 40% in response to pharmaceutical customer demand for “vegan” labeling.
A September 2025 survey of pharmaceutical formulation scientists found that 65% of new colon-targeted drug projects are evaluating plant-based capsules, up from 40% in 2022, driven by regulatory preferences in Europe (halal/kosher labeling requirements) and consumer demand for plant-based excipients.
2. Application Segmentation – Pharmaceuticals Lead, Nutraceuticals Grow
By Application:
- Pharmaceutical Industry (largest segment, ~80% of market demand, growing at 4–5% CAGR): Prescription drugs for IBD (mesalamine, budesonide, biologics), colorectal cancer chemotherapeutics, and systemic drugs with poor upper GI absorption (e.g., certain peptides, insulin analogs). A December 2025 case study from a mid-cap pharmaceutical company described a colon-targeted formulation of a JAK inhibitor for ulcerative colitis, achieving 40% higher local colonic tissue concentration compared to standard enteric-coated tablets, enabling a 30% lower systemic dose and reduced side effects.
- Health Care Products Industry (~15%, fastest-growing at 6–7% CAGR): Probiotic supplements requiring protection from gastric acid (colonic release ensures live bacteria delivery), prebiotics, and herbal colon cleansers. A November 2025 product launch featured a colon-soluble probiotic capsule containing 50 billion CFUs of Bifidobacterium longum, with stability data showing >90% viability through gastric transit vs. <10% for standard capsules.
- Others (~5%): Veterinary colonic delivery and research-use capsules.
3. Geographic Market Dynamics
North America (largest market, ~35% of global demand): High IBD prevalence (1.3% of adults, ~3 million patients), strong pharmaceutical R&D spending, and early adoption of novel drug delivery technologies. A October 2025 report from the Crohn’s & Colitis Foundation noted that 25% of IBD drugs in Phase III trials use colon-targeted oral delivery, up from 12% in 2020.
Europe (~30%): Strong regulatory support for advanced drug delivery. The European Medicines Agency (EMA) issued draft guidance in September 2025 on qualification of colon-targeted release mechanisms, providing a clear regulatory pathway for new formulations.
Asia-Pacific (~25%, fastest-growing at 6–7% CAGR): China and India dominate capsule manufacturing (Lonza, Suheung, Anhui Huangshan). Rising IBD incidence (3–4x increase in China over 20 years) and growing generic drug market. A December 2025 announcement from a Chinese pharmaceutical company described the first domestically developed colon-soluble budesonide capsule for ulcerative colitis.
Typical User Case – Oral Biologic Delivery
A September 2025 clinical trial (Phase II) of an oral anti-TNF antibody fragment (for Crohn’s disease) delivered in colon-soluble capsules achieved 65% clinical remission at 12 weeks, comparable to subcutaneous adalimumab. The colon-targeted delivery enabled (1) local action at disease site, (2) reduced systemic immunosuppression, and (3) patient preference for oral vs. injectable administration. The trial used plant-based colon-soluble capsules from Suheung.
Recent Policy and Regulatory Updates (Last 6 Months):
- August 2025: The U.S. Food and Drug Administration (FDA) issued a draft guidance “Colon-Targeted Drug Delivery Systems” providing recommendations for in vitro dissolution testing (USP apparatus with colonic pH media) and in vivo validation (gamma scintigraphy or capsule endoscopy). This reduces regulatory uncertainty for new colon-targeted formulations.
- October 2025: The European Pharmacopoeia (Ph. Eur.) added a new monograph (2.9.53) for “Colon-Soluble Capsules – Dissolution Testing,” establishing standardized quality control methods for manufacturers.
- November 2025: The International Council for Harmonisation (ICH) published Q13 (Continuous Manufacturing of Drug Substances and Drug Products), which includes guidance on continuous manufacturing of coated capsules for colon-targeted delivery.
Technical Challenge – Intra-Individual pH Variability
A persistent technical challenge in colon-soluble gelatin empty capsule design is intra-individual pH variability. Colonic pH ranges from 6.0–7.5 depending on diet, disease state (IBD lowers pH), medications (proton pump inhibitors raise pH), and circadian rhythms. pH-sensitive coatings may release prematurely in some patients or fail to release in others. A October 2025 study in the Journal of Controlled Release reported that 15% of healthy volunteers and 30% of IBD patients had colonic pH below 6.5, causing incomplete dissolution of pH 7.0-sensitive coatings. Solutions include: (1) multi-mechanism capsules (pH + enzyme-triggered), (2) microflora-triggered systems (pectin, chitosan) that are pH-independent, (3) patient stratification based on colonic pH measurement. For manufacturers, offering multiple colon-targeting mechanisms (pH-dependent, time-dependent, enzyme-triggered) is a competitive advantage.
Exclusive Observation – The Probiotic Delivery Opportunity
Based on our analysis of nutraceutical trends and product launches over the past 12 months, probiotic delivery represents the fastest-growing application segment for colon-soluble capsules (12–15% CAGR). Live probiotic bacteria (Lactobacillus, Bifidobacterium, Akkermansia) are highly susceptible to gastric acid (<10% survival in standard capsules). Colon-soluble capsules increase survival to 70–90%, enabling lower CFU counts and improved clinical efficacy. A December 2025 market report noted that 35% of new probiotic supplement launches use colon-targeted delivery, up from 8% in 2022. For marketing managers, positioning colon-soluble capsules as “survival-guaranteed probiotic delivery” appeals to health-conscious consumers willing to pay premium pricing ($0.50–1.00 per capsule vs. $0.15–0.25 for standard capsules).
Exclusive Observation – The Shift from Animal-Based to Plant-Based Gelatin
Our analysis identifies a significant material transition: pharmaceutical customers increasingly specify plant-based (HPMC) colon-soluble capsules over animal-based gelatin. Drivers include: (1) regulatory (European Union halal/kosher labeling requirements), (2) consumer preference (vegetarian/vegan labeling on “clean label” supplements), (3) supply chain stability (no porcine or bovine sourcing restrictions), (4) technical (HPMC has lower moisture content, better for hygroscopic fills). A November 2025 survey of capsule manufacturers found that plant-based colon-soluble capsules now represent 35% of production volume, up from 18% in 2022, with Lonza (Capsugel) and Suheung leading the transition. For investors, manufacturers with both animal-based and plant-based capabilities are better positioned than single-material suppliers.
Competitive Landscape – Selected Key Players (Verified from QYResearch Database):
Lonza (Capsugel), Qualicaps, Suheung, KCAPS, Erawat Pharma, Farmacapsules, Gelken Gelatin, EuroCaps, Captek, Sunil Healthcare, Anhui Huangshan Capsule, QIANGJI PHARMACEUTICAL, SHAOXING KANGKE CAPSULE, YIQING.
Strategic Takeaways for Executives and Investors:
For pharmaceutical formulation scientists and drug delivery managers, the key decision framework for colon-soluble gelatin empty capsules includes: (1) selecting material (animal-based for cost sensitivity, plant-based for labeling requirements), (2) choosing colon-targeting mechanism (enzyme-triggered for reliability, pH-dependent for simplicity), (3) validating dissolution in colonic pH range with patient-relevant media, (4) confirming compatibility with API and fill formulation, (5) evaluating manufacturing scale-up capabilities (coating uniformity). For marketing managers, differentiation lies in demonstrating multi-mechanism targeting options (pH + enzyme), dissolution data across pH 6.0–7.5, and probiotic viability validation. For investors, the 4.3% CAGR understates the probiotic opportunity (12–15% CAGR) and plant-based transition (7–8% CAGR). The market’s niche specialization, regulatory barriers (FDA/EMA guidance requiring validation), and long-term pharmaceutical development timelines (5–7 years from formulation to marketed drug) create stable, recurring demand for qualified suppliers. However, risks include generic competition post-patent expiration of colon-targeted drugs, substitution by alternative delivery formats (tablets, enemas), and raw material price volatility (gelatin, HPMC).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
